Cell assay for the identification of amyloid inhibitors in systemic AA amyloidosis

Area of Science:

• Biochemistry
• Cell Biology
• Medical Science

Background:

• Systemic AA amyloidosis, a complication of chronic inflammatory diseases, remains life-threatening despite anti-inflammatory treatments.
• Novel therapies targeting the amyloidogenic pathway are needed for patients with poor prognoses.

Purpose of the Study:

• To utilize a cell culture model to identify compounds inhibiting amyloid formation in systemic AA amyloidosis.
• To explore therapeutic strategies targeting both protein self-assembly and cellular protein machinery.

Main Methods:

• A cell culture model mimicking in vivo AA amyloid deposit formation was used.
• Five known amyloid inhibitory compounds and compounds targeting protein quality control were screened.
• Inhibition of serum amyloid A1 (SAA1) fibril formation was assessed.

Main Results:

• Epigallocatechin gallate (EGCG) significantly inhibited the formation of SAA1-derived fibrils in the cell model.
• The autophagy inhibitor wortmannin reduced amyloid formation, while other tested compounds did not show substantial effects.
• The cell model proved effective for identifying compounds with amyloid inhibitory activity.

Conclusions:

• Targeting protein self-assembly directly, such as with EGCG, can inhibit AA amyloidosis.
• Modulating cellular protein machinery, like with wortmannin, offers a potential therapeutic avenue.
• The developed cell model is a valuable tool for discovering novel anti-amyloidosis compounds.